Effects of Pitavastatin on Pressure Overload-Induced Heart Failure in Mice

DOI Web Site PubMed 被引用文献12件 参考文献76件
  • Kameda Yoshihito
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
  • Hasegawa Hiroshi
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
  • Kubota Akihiko
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
  • Tadokoro Hiroyuki
    Department of Bio-Medical Engineering, Tokai University School of High-Technology for Human Welfare
  • Kobayashi Yoshio
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
  • Komuro Issei
    Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
  • Takano Hiroyuki
    Department of Molecular Cardiovascular Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University

この論文をさがす

抄録

Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), which are widely used to lower plasma cholesterol levels, have been reported to have various pleiotropic effects such as protective effect of endothelial cells, angiogenic effect, antioxidant effect and anti-inflammatory effect. It is unclear, however, whether statins have any effects on the progression from left ventricular (LV) hypertrophy to heart failure in the established hypertrophied heart. Methods and Results: C57BL/6 mice were treated with pitavastatin (pitava) or vehicle (control) from 2 weeks (established hypertrophy stage) after transverse aortic constriction (TAC) and the treatment was continued for 4 weeks. Pitavastatin significantly inhibited the progression from LV hypertrophy to heart failure as assessed on echocardiography. The cardiomyocyte cross-sectional area was significantly increased in the control group compared to the sham-operated mice (sham group), but it was not significantly different between the control group and the pitava group at 6 weeks after TAC. Moreover, pitavastatin induced myocardial angiogenesis (ratio of number of endothelial cells to cardiomyocytes) and decreased the myocardial fibrosis and oxidative stress. The expression of angiopoietin-1 in the heart was significantly increased by pitavastatin at 6 weeks after TAC. Conclusions: Pitavastatin has preventive effects on the progression of heart failure even in the hypertrophied heart. (Circ J 2012; 76: 1159-1168)<br>

収録刊行物

  • Circulation Journal

    Circulation Journal 76 (5), 1159-1168, 2012

    一般社団法人 日本循環器学会

被引用文献 (12)*注記

もっと見る

参考文献 (76)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ